TY  - BOOK
AU  - Apalla,Zoe
AU  -  Sidiropoulos,Theodoros
AU  -  Kampouropoulou,Evaggelia
AU  -  Papageorgiou,Marina
AU  -  Lallas,Aimilios
AU  -  Lazaridou,Elizabeth
AU  -  Smaragdi,Maria
AU  -  Delli,Florentina
TI  - Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria
PY  - 2020///.
							
N1  - 5
N2  - Background: Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) not responding to antihistamines. Data on omalizumab use in real-world settings and in different populations are lacking. Objectives: To record our five-year experience of omalizumab use in patients with refractory CSU in a real-world setting. Materials & Methods: A retrospective analysis of medical records of 80 patients with refractory CSU was performed. Demographic, and clinical characteristics, patterns of response, discontinuation strategies and rate of recurrence were analysed. Results: Eighty individuals were included. UAS7 and DLQI significantly decreased from baseline. Complete response was achieved in 86.3%. Late response was observed at 27.5% of the patients. After discontinuation, 21.7% of patients reinitiated omalizumab due to relapse. The mean number of omalizumab administrations up to first discontinuation was 6.8 (based on an approach to shorten the treatment interval). Only 15.0% of patients experienced adverse events during treatment. Conclusion: Omalizumab, with long-term management, was highly effective and safe in achieving control of refractory CSU, with more favourable responses compared to Phase III clinical trials
UR  - https://shs.cairn.info/revue-european-journal-of-dermatology-2020-6-page-716?lang=en&redirect-ssocas=7080
ER  -